Page 1

DICOT PHARMA INTERIM REPORT APRIL - JUNE 2026 Second quarter 2026 January - June 2026 Net sales amounted to MSEK 0.0 ( 0.0 ) The result after financial items amounted to MSEK -18.4 ( -24.3 ) Earnings per share amounted to SEK -0.01 ( -0.01 ) Net sales amounted to MSEK 0.0 ( 0.0 ) The result after financial items amounted to MSEK -33.2 ( -47.2 ) Earnings per share amounted to SEK -0.02 ( -0.03 ) " The successful capital raise provides us with the financial resources to carry out the planned phase 2b study of LIB - 01 , which has the potential to revolutionize the treatment of erectile dysfunction . Elin Trampe , CEO Dicot Pharma The report will be presented in a webcast to be published on August 20 at 10:00 a.m. on https://www.dicotpharma.com/en/media/films/ . Dicot Pharma AB ( publ ) 559006-3490 S : t Olofsgatan 11A www.dicotpharma.com 753 21 Uppsala